Synthesis and cardioprotective effect of a novel anti-ischemic/reperfused injury compound.
- Author:
Wen-chong LIU
1
;
Xiao-li SUN
;
Le-le JI
;
Hai-bo WANG
;
Hai-feng ZHANG
;
Jia LI
;
Lei SHI
;
Lin-lin JING
;
Feng GAO
Author Information
1. Department of Physiology, Fourth Military Medical University, Xi'an 710032, China.
- Publication Type:Journal Article
- MeSH:
Animals;
Cardiotonic Agents;
chemical synthesis;
chemistry;
pharmacology;
Creatine Kinase;
blood;
Electrocardiography;
Hydrogen Peroxide;
blood;
Isosorbide Dinitrate;
analogs & derivatives;
chemical synthesis;
chemistry;
pharmacology;
L-Lactate Dehydrogenase;
blood;
Male;
Malondialdehyde;
blood;
Myocardial Reperfusion Injury;
blood;
pathology;
physiopathology;
prevention & control;
Myocardium;
pathology;
Nitric Oxide;
blood;
Random Allocation;
Rats;
Rats, Sprague-Dawley;
Superoxide Dismutase;
blood
- From:
Acta Pharmaceutica Sinica
2009;44(3):321-326
- CountryChina
- Language:Chinese
-
Abstract:
The aim of present study is to investigate the cardioprotective effect of a new compound acetyl ferulaic isosorbide (AFI), composed of ferulaic acid (FA) and isosorbide mononitrate (ISMN) by esterification in myocardial ischemia/reperfusion (MI/R). Male Sprague-Dawley rats, subjected to 30 minutes of myocardial ischemia and 3 hours of reperfusion, randomly received one of the following treatments separately: SHAM, I/R (MI/R + solvent), SF (MI/R+SF, 40 mg x kg(-1), ig), ISMN (MI/R + ISMN, 30 mg x kg(-1), ig), SF + ISMN (MI/R + SF + ISMN, 40 mg x kg(-1) + 30 mg x kg(-1), ig) and AFI (MI/R + AFI, 10 mg x kg(-1), ig). Left ventricle developed pressures (LVDP) and the maximal first derivative of developed pressure ( +/-dP / dtmax) were monitored throughout the experiments. Myocardial infarction size, serum creatine kinase (CK) activity, lactate dehydrogenase (LDH) activity, superoxide dismutase (SOD) activity, hydrogen peroxide (H2O2), malondialdehyde (MDA) and nitric oxide (NO) production were determined at the end of reperfusion. Compared with SF, ISMN or SF + ISMN treatment groups, AFI treatment decreased infarction size (n=8, P < 0.01), improved cardiac function as evidenced by increased LVDP and +/- dP/dtmax (n=8, P < 0.05), increased serum SOD activity, reduced serum CK and LDH activities, H2O2 and MDA production (n=8, P < 0.05). The new compound AFI showed a stronger cardioprotective effect against MI/R injury than SF, ISMN or their combined administration did.
